在未选择的转移性结直肠癌患者中，贝伐单抗与基于5-氟尿嘧啶的化疗联合输注10分钟的安全性。 - Suppr | 超能文献

Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.

作者信息

Coriat Romain, Mir Olivier, Chaussade Stanislas, Goldwasser François

出版信息

Dig Liver Dis. 2011 Mar;43(3):248-9. doi: 10.1016/j.dld.2010.10.013. Epub 2010 Dec 9.

DOI:10.1016/j.dld.2010.10.013

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.在未选择的转移性结直肠癌患者中，贝伐单抗与基于5-氟尿嘧啶的化疗联合输注10分钟的安全性。

Dig Liver Dis. 2011 Mar;43(3):248-9. doi: 10.1016/j.dld.2010.10.013. Epub 2010 Dec 9.

2

Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.在一组非选择性转移性结直肠癌患者中，短期输注贝伐单抗联合基于5-氟尿嘧啶的化疗作为一线治疗方案。

Acta Oncol. 2010 Apr;49(3):395-6. doi: 10.3109/02841860903428184.

3

The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.转移性结直肠癌患者接受短时间贝伐珠单抗输注的可行性。

Anticancer Res. 2014 Feb;34(2):1053-6.

4

[Complications of chemotherapy in combination with bevacizumab for treating metastatic colorectal cancer].[化疗联合贝伐单抗治疗转移性结直肠癌的并发症]

Vopr Onkol. 2010;56(5):613-6.

5

Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.一项III期多中心随机临床试验，旨在评估辅酶/5-氟尿嘧啶/贝伐单抗与亚叶酸钙/5-氟尿嘧啶/贝伐单抗作为转移性结直肠癌初始治疗的安全性和有效性。

Clin Colorectal Cancer. 2006 Sep;6(3):229-34. doi: 10.3816/CCC.2006.n.042.

6

Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.贝伐珠单抗联合卡培他滨作为一线治疗老年转移性结直肠癌患者的 II 期研究。

Anticancer Drugs. 2011 Feb;22(2):191-7. doi: 10.1097/CAD.0b013e3283417f3e.

7

Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.贝伐珠单抗联合氟嘧啶类化疗作为转移性结直肠癌的一线治疗。

Health Technol Assess. 2010 Oct;14(Suppl. 2):47-53. doi: 10.3310/hta14suppl2/07.

8

Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.贝伐单抗联合氟尿嘧啶和亚叶酸钙治疗晚期难治性结直肠癌的II期多中心试验：一项美国国立癌症研究所治疗转诊中心试验TRC-0301

J Clin Oncol. 2006 Jul 20;24(21):3354-60. doi: 10.1200/JCO.2005.05.1573.

9

Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.贝伐单抗联合化疗：转移性结直肠癌患者的一线治疗

Semin Oncol. 2006 Oct;33(5 Suppl 10):S8-14. doi: 10.1053/j.seminoncol.2006.08.005.

10

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.贝伐单抗联合氟尿嘧啶和亚叶酸钙：一线转移性结直肠癌的有效治疗方案。

J Clin Oncol. 2005 May 20;23(15):3502-8. doi: 10.1200/JCO.2005.10.017.

引用本文的文献

1

Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients.贝伐珠单抗 7.5mg/kg 输注 10 分钟治疗非小细胞肺癌患者的安全性。

Invest New Drugs. 2012 Aug;30(4):1756-60. doi: 10.1007/s10637-011-9690-9. Epub 2011 May 26.